This database contains 651 studies, archived under the term: "Cognition"
Click here to filter this large number of results.
Longitudinal medication usage in Alzheimer disease patients
Zhu, Carolyn W.,
Livote, Elayne E.,
Kahle-Wrobleski, Kristin,
Scarmeas, Nikolaos,
Albert, Marilyn,
Brandt, Jason,
Blacker, Deborah,
Sano, Mary,
Stern, Yaakov
This study examined in detail patterns of cholinesterase inhibitors (ChEIs) and memantine use and explored the relationship between patient characteristics and such use. Patients with probable Alzheimer disease AD (n=201) were recruited from the Predictors Study in 3 academic AD centers and followed from early disease stages for up to 6 years. Random effects logistic […]
Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: A pilot study
Wong, G. K. C.,
Wong, R.,
Mok, V.,
Wong, A.,
Fan, D.,
Leung, G.,
Chan, A.,
Poon, W. S.
Background and objective: Rivastigmine has been shown to be effective for patients with mild-to-moderate Alzheimer’s disease. Its effect on cognitive impairment after aneurysmal subarachnoid haemorrhage has not been previously studied. The aim of the study is to evaluate the efficacy and safety of rivastigmine 3 mg day over 12 weeks in patients with aneurysmal subarachnoid […]
Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer’s disease: A longitudinal functional MRI study
Thiyagesh, Subha N.,
Farrow, Tom F. D.,
Parks, Randolph W.,
Accosta-Mesa, Hector,
Hunter, Michael D.,
Young, Claire,
Wilkinson, lain D.,
Woodruff, Peter W. R.
Background/Aims: Visuospatial impairments are known to occur in Alzheimer’s disease (AD). We hypothesised that functional magnetic resonance imaging (fMRI) response in task-related brain regions would be impaired in patients with AD during the task and that treatment with acetyl cholinesterase inhibitors would enhance activations in brain regions concerned with this visual perceptual processing. Method: Ten […]
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Schmitt, Frederick A.,
Aarsland, Dag,
Brønnick, Kolbjørn S.,
Meng, Xiangyi,
Tekin, Sibel,
Olin, Jason T.
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]
No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease
Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]
Vitamins B₁₂, B₆, and folic acid for cognition in older men
Ford, A. H.,
Flicker, L.,
Alfonso, H.,
Thomas, J.,
Clarnette, R.,
Martins, R.,
Almeida, O. P.
[Correction Notice: An erratum for this article was reported in Vol 77(8) of Neurology (see record [rid]2011-21984-022[/rid]). In the original article, the daily dose of vitamin B12 used in the trial was reported as 400 μg, but it should have been 500 μg.] Objective: To investigate whether supplementing older men with vitamins B12, B6, and […]